Published in Am J Pathol on November 01, 2004
Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol (2006) 1.68
In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J Neurosci (2011) 1.19
Knock-out and transgenic mouse models of tauopathies. Neurobiol Aging (2007) 1.14
Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2012) 1.07
Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflammation (2012) 1.03
Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Front Psychiatry (2010) 1.03
Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol Dis (2014) 0.99
Modulation of inflammation in transgenic models of Alzheimer's disease. J Neuroinflammation (2014) 0.99
Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain (2015) 0.96
Modulation of adult-born neurons in the inflamed hippocampus. Front Cell Neurosci (2013) 0.94
The role of tau in Alzheimer's disease and related disorders. CNS Neurosci Ther (2010) 0.91
Role of microglia in ethanol's apoptotic action on hypothalamic neuronal cells in primary cultures. Alcohol Clin Exp Res (2010) 0.91
Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia. Brain Behav (2012) 0.90
Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci U S A (2005) 0.88
Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. Hum Mol Genet (2012) 0.86
Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener Dis (2011) 0.84
Cell-cycle markers in a transgenic mouse model of human tauopathy: increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. Am J Pathol (2006) 0.84
Review: tauopathy in the retina and optic nerve: does it shadow pathological changes in the brain? Mol Vis (2012) 0.82
Sevoflurane induces tau phosphorylation and glycogen synthase kinase 3β activation in young mice. Anesthesiology (2014) 0.82
A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatry (2014) 0.81
Redistribution of DAT/α-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease. PLoS One (2011) 0.80
Analyzing dendritic spine pathology in Alzheimer's disease: problems and opportunities. Acta Neuropathol (2015) 0.80
Microglia display modest phagocytic capacity for extracellular tau oligomers. J Neuroinflammation (2014) 0.80
Accelerated neurodegeneration and neuroinflammation in transgenic mice expressing P301L tau mutant and tau-tubulin kinase 1. Am J Pathol (2014) 0.80
Targeting Neural Hyperactivity as a Treatment to Stem Progression of Late-Onset Alzheimer's Disease. Neurotherapeutics (2017) 0.80
Impaired plasticity of cortical dendritic spines in P301S tau transgenic mice. Acta Neuropathol Commun (2013) 0.79
Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain (2016) 0.77
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol (2015) 0.77
Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic rats. Am J Neurodegener Dis (2016) 0.77
Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD. Acta Neuropathol Commun (2016) 0.76
Evidence of Tau Hyperphosphorylation and Dystrophic Microglia in the Common Marmoset. Front Aging Neurosci (2016) 0.75
Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation. Glia (2015) 0.75
Early and progressive deficit of neuronal activity patterns in a model of local amyloid pathology in mouse prefrontal cortex. Aging (Albany NY) (2016) 0.75
Retracted Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease. Am J Neurodegener Dis (2016) 0.75
A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. Neurol Ther (2017) 0.75
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology (1988) 6.79
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A (1989) 5.97
Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol (1998) 5.42
Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology (1996) 4.42
Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron (1992) 4.22
Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci (1999) 3.90
Microglia promote the death of developing Purkinje cells. Neuron (2004) 3.42
Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron (1993) 3.30
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett (1995) 3.15
Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science (2000) 3.12
Phagocytosis promotes programmed cell death in C. elegans. Nature (2001) 3.12
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci (2002) 2.80
Engulfment genes cooperate with ced-3 to promote cell death in Caenorhabditis elegans. Nature (2001) 2.64
Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem (2001) 2.40
Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol (1992) 2.01
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (2000) 1.92
Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci U S A (1998) 1.77
Immune system response in Alzheimer's disease. Can J Neurol Sci (1989) 1.75
Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci U S A (2002) 1.66
Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol (2001) 1.55
Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol (1989) 1.54
Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci (2001) 1.53
Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett (1999) 1.53
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol (2002) 1.52
Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol (1999) 1.49
Microglia-derived nerve growth factor causes cell death in the developing retina. Neuron (1998) 1.47
Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience (1998) 1.45
Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J Neurosci (2002) 1.42
Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol (2001) 1.40
Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol (1998) 1.34
FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci (2001) 1.22
Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett (1996) 1.16
Immunoreactive interleukin-1 beta localization in the rat forebrain. Brain Res (1990) 1.10
A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J (2003) 1.10
Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol (2004) 1.08
Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch Biochem Biophys (2000) 1.04
Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. Exp Gerontol (2001) 0.96
Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport (1997) 0.95
Activated microglia in dementia with Lewy bodies. Neurology (2000) 0.94
Interleukin-1 beta activates expression of cyclooxygenase-2 and inducible nitric oxide synthase in primary hippocampal neuronal culture: platelet-activating factor as a preferential mediator of cyclooxygenase-2 expression. J Neurosci Res (1999) 0.93
Microglia are associated with the extracellular neurofibrillary tangles of Alzheimer disease. Brain Res (1991) 0.93
Macrophage-derived tumor necrosis factor alpha, an early developmental signal for motoneuron death. J Neurosci (2004) 0.90
Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann Neurol (2000) 0.88
Neurofibrillary tangles of Guam parkinson-dementia are associated with reactive microglia and complement proteins. Brain Res (1996) 0.87
Evidence that neurofibrillary tangles undergo glial modification. Acta Neuropathol (1992) 0.87
Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50
A century of Alzheimer's disease. Science (2006) 5.84
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet (2005) 4.21
GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov (2004) 3.93
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci (2002) 2.80
Tau pathology and neurodegeneration. Lancet Neurol (2013) 2.66
Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A (2013) 2.27
Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One (2010) 2.15
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem (2004) 2.11
Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem (2002) 2.07
Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J (2003) 2.07
p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J (2005) 1.90
Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci (2006) 1.89
Proteasomal degradation of tau protein. J Neurochem (2002) 1.88
Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry (2006) 1.69
Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A (2003) 1.67
Relations of arterial stiffness and endothelial function to brain aging in the community. Neurology (2013) 1.60
Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett (2004) 1.60
Hereditary frontotemporal dementia caused by Tau gene mutations. Brain Pathol (2007) 1.57
Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci (2006) 1.57
Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain (2012) 1.55
Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem (2003) 1.47
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain (2010) 1.38
Interaction of tau protein with the dynactin complex. EMBO J (2007) 1.33
A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol (2014) 1.32
Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am J Pathol (2007) 1.32
Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain (2009) 1.31
PART is part of Alzheimer disease. Acta Neuropathol (2015) 1.31
Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis (2002) 1.25
Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.23
A simple algorithm locates beta-strands in the amyloid fibril core of alpha-synuclein, Abeta, and tau using the amino acid sequence alone. Protein Sci (2007) 1.22
White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. J Neuropathol Exp Neurol (2008) 1.21
Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 1.21
Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope. J Neurochem (2006) 1.21
Pathogenesis of the tauopathies. J Mol Neurosci (2011) 1.21
The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain (2007) 1.18
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett (2009) 1.17
Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). J Neurochem (2004) 1.17
Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord (2012) 1.17
Stress- and mitogen-induced phosphorylation of the synapse-associated protein SAP90/PSD-95 by activation of SAPK3/p38gamma and ERK1/ERK2. Biochem J (2004) 1.16
In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem (2008) 1.13
Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies. FEBS Lett (2007) 1.12
Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol Dis (2006) 1.10
Cysteine misincorporation in bacterially expressed human alpha-synuclein. FEBS Lett (2006) 1.10
Sequence Determinants for Amyloid Fibrillogenesis of Human alpha-Synuclein. J Mol Biol (2007) 1.09
Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant. Acta Neuropathol (2012) 1.09
Human stem cell-derived neurons: a system to study human tau function and dysfunction. PLoS One (2010) 1.07
A role for FKBP52 in Tau protein function. Proc Natl Acad Sci U S A (2010) 1.07
Cell-mediated neuroprotection in a mouse model of human tauopathy. J Neurosci (2010) 1.07
Circadian clocks and neurodegenerative diseases: time to aggregate? Curr Opin Neurobiol (2013) 1.07
Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38delta at Thr50 promotes microtubule assembly. J Cell Sci (2005) 1.06
The value of incomplete mouse models of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 1.06
Tau gene (MAPT) sequence variation among primates. Gene (2004) 1.06
"Prion-like" templated misfolding in tauopathies. Brain Pathol (2013) 1.06
Alpha-synuclein adopts an alpha-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation. Biochemistry (2006) 1.04
Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease. J Neurochem (2009) 1.04
Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS One (2010) 1.03
A Raman optical activity study of rheomorphism in caseins, synucleins and tau. New insight into the structure and behaviour of natively unfolded proteins. Eur J Biochem (2002) 1.03
Association between tau H2 haplotype and age at onset in frontotemporal dementia. Arch Neurol (2005) 1.02
Frontotemporal dementia with tau pathology. Neurodegener Dis (2007) 1.02
Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies. J Neurosci (2013) 1.02
Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability. Neurobiol Aging (2009) 1.01
Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene]. FEBS Lett (2008) 1.00
Inhibition of alpha-synuclein fibril assembly by small molecules: analysis using epitope-specific antibodies. FEBS Lett (2009) 1.00
Early behavioural markers of disease in P301S tau transgenic mice. Behav Brain Res (2009) 0.99
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One (2013) 0.98
Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol (2013) 0.97
Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One (2012) 0.97
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain (2012) 0.96
A novel role for Sema3A in neuroprotection from injury mediated by activated microglia. J Neurosci (2006) 0.96
Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Mov Disord (2011) 0.95
Abnormal processing of tau in the brain of aged TgCRND8 mice. Neurobiol Dis (2007) 0.92
Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene. Acta Neuropathol (2005) 0.92
A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease. Ann Neurol (2002) 0.92
Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra. Exp Neurol (2013) 0.91
Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Parkinsons Dis (2013) 0.91
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. Brain (2012) 0.91
A comparison of the biochemical modifications caused by toxic and non-toxic protein oligomers in cells. J Cell Mol Med (2011) 0.90
Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Exp Neurol (2008) 0.90
Alpha-synuclein dysfunction in Lewy body diseases. Mov Disord (2005) 0.90
Reduced axonal transport and increased excitotoxic retinal ganglion cell degeneration in mice transgenic for human mutant P301S tau. PLoS One (2012) 0.89